Regeneron’s COVID-19 Antibody Cocktail Shown to Reduce COVID-19 Progression in Trials
Data from phase three trials of the drug REGEN-COV found symptomatic infections were reduced by 81%.
The trial studied more than 1,500 people who had not been infected with the virus, but lived with someone who tested positive.
The company says there was 72% protection against symptomatic infections in the first week and 93% protection in later weeks.
Those who did get symptoms had them resolved in one week.
The trials tested the cocktail as an injection.
Right now, the cocktail is only available in the U.S. as an IV treatment.
Regeneron will request an expansion to its emergency use authorization.